Condition
Castration Resistant Metastatic Prostate Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Castration Resistant Metastatic Prostate Cancer clinical trials that are recruiting, at sites in 3 countries (most in United States (2), Netherlands (1), France (1)). By phase: Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Castration Resistant Metastatic Prostate Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| AKY-2519 (B7‑H3 targeted radioligand) for metastatic castration‑resistant prostate cancer | Phase 1 | Irvine, California and 7 other locations | Recruiting | May 12, 2026 |
| Targeted radiotherapy to up to three growing prostate cancer spots in castration‑resistant disease | Phase 2 | Groningen and 1 other locations | Recruiting | Jun 26, 2025 |
| Using molecular markers to predict treatment response in advanced prostate cancer | — | Clermont-Ferrand and 4 other locations | Recruiting | Sep 19, 2024 |
| Sequential Testosterone and Enzalutamide treatment for advanced prostate cancer | Phase 2 | San Diego, California and 5 other locations | Recruiting | Apr 27, 2020 |
All recruiting trials (4)
-
AKY-2519 (B7‑H3 targeted radioligand) for metastatic castration‑resistant prostate cancer
This trial tests whether AKY‑2519, a B7‑H3–targeted radioactive medicine used for imaging and treatment, is safe and can shrink tumors in men with metastatic castration‑resistant prostate cancer, including those who have had prior 177Lu‑PSMA‑617.
-
Targeted radiotherapy to up to three growing prostate cancer spots in castration‑resistant disease
This trial will try adding targeted radiotherapy to up to three progressing spots to see if it can delay the next systemic treatment and extend disease control in men with oligoprogressive castration‑resistant prostate cancer.
-
Using molecular markers to predict treatment response in advanced prostate cancer
This study is testing if certain markers in tumor DNA can help doctors predict how well a new treatment for advanced prostate cancer will work for patients.
-
Sequential Testosterone and Enzalutamide treatment for advanced prostate cancer
This study is testing if alternating high-dose testosterone with enzalutamide can help men with advanced prostate cancer do better than just taking enzalutamide alone.
Related topics
Quick answers
How many Castration Resistant Metastatic Prostate Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in United States (2 trials), Netherlands (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.